144 related articles for article (PubMed ID: 38322501)
1. The Effect of a Loading Dose Regimen in the Switch to Brolucizumab for Patients with Aflibercept-Resistant nAMD.
Kamao H; Mitsui E; Date Y; Goto K; Mizukawa K; Miki A
J Ophthalmol; 2024; 2024():3673930. PubMed ID: 38322501
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
[TBL] [Abstract][Full Text] [Related]
3. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
4. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
[TBL] [Abstract][Full Text] [Related]
6. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS
Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020
[TBL] [Abstract][Full Text] [Related]
7. Short-term Efficacy and Safety of Intravitreal Brolucizumab Injection for Treatment-Naive Exudate Age-related Macular Degeneration: A Multicenter Study.
Kim J; Lee SJ; Park TK; Sun HJ; Kim HD; Cho IH; Han JW; Choi KS
Korean J Ophthalmol; 2023 Oct; 37(5):365-372. PubMed ID: 37562440
[TBL] [Abstract][Full Text] [Related]
8. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
9. Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.
Kim M; Kang JE; Park YG
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38929964
[No Abstract] [Full Text] [Related]
10. Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration.
Hama Y; Miyata M; Ooto S; Tamura H; Ueda-Arakawa N; Muraoka Y; Miyake M; Takahashi A; Wakazono T; Uji A; Yamashiro K; Tsujikawa A
Graefes Arch Clin Exp Ophthalmol; 2023 Jul; 261(7):1871-1881. PubMed ID: 36735070
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
[No Abstract] [Full Text] [Related]
12. Brolucizumab for persistent macular fluid in neovascular age-related macular degeneration after prior anti-VEGF treatments.
Hussain RM; Neal A; Yannuzzi NA; Patel KH; Huo S; Hariprasad SM; Bhatia SP
Ther Adv Ophthalmol; 2021; 13():25158414211055964. PubMed ID: 34926990
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
[TBL] [Abstract][Full Text] [Related]
14. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA;
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741
[TBL] [Abstract][Full Text] [Related]
15. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
Kikushima W; Sakurada Y; Fukuda Y; Matsubara M; Kotoda Y; Sugiyama A; Kashiwagi K
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111318
[TBL] [Abstract][Full Text] [Related]
16. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
17. Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment.
Ueji N; Mase Y; Kubo A; Matsubara H; Chujo S; Matsui Y; Kondo M
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893574
[No Abstract] [Full Text] [Related]
18. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study.
Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ
Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210
[TBL] [Abstract][Full Text] [Related]
19. Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration.
Kato N; Haruta M; Furushima K; Arai R; Matsuo Y; Yoshida S
Clin Ophthalmol; 2023; 17():1187-1192. PubMed ID: 37096209
[TBL] [Abstract][Full Text] [Related]
20. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
